These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma. Melief SM; Visser M; van der Burg SH; Verdegaal EME Cancer Immunol Immunother; 2017 Jul; 66(7):913-926. PubMed ID: 28401257 [TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy involving recombinant human M-CSF and R24 anti-melanoma antibody induces human T-cell infiltration into human melanoma xenografts. Conlon KC; Anver MR; Longo DL; Ortaldo JR; Murphy WJ J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):317-23. PubMed ID: 8941871 [TBL] [Abstract][Full Text] [Related]
10. Melanoma-induced immunosuppression and its neutralization. Umansky V; Sevko A Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515 [TBL] [Abstract][Full Text] [Related]
11. The adoptive transfer of cultured T cells for patients with metastatic melanoma. Yang JC Clin Dermatol; 2013; 31(2):209-19. PubMed ID: 23438384 [TBL] [Abstract][Full Text] [Related]
12. [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"]. Martins F; Orcurto A; Michielin O; Coukos G Rev Med Suisse; 2016 May; 12(519):989-93. PubMed ID: 27424426 [TBL] [Abstract][Full Text] [Related]
13. Melanoma immunotherapy: new dreams or solid hopes? Maio M; Parmiani G Immunol Today; 1996 Sep; 17(9):405-7. PubMed ID: 8854555 [No Abstract] [Full Text] [Related]
14. Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. Bowers JS; Nelson MH; Majchrzak K; Bailey SR; Rohrer B; Kaiser AD; Atkinson C; Gattinoni L; Paulos CM JCI Insight; 2017 Mar; 2(5):e90772. PubMed ID: 28289713 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for advanced melanoma: Current knowledge and future directions. Nakamura K; Okuyama R J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423 [TBL] [Abstract][Full Text] [Related]
16. A role of immunotherapy in metastatic malignant melanoma. Allen T; Gundrajakuppam L Cent Nerv Syst Agents Med Chem; 2012 Sep; 12(3):182-8. PubMed ID: 22697295 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and experimental approaches for metastatic melanoma. Atkins MB Hematol Oncol Clin North Am; 1998 Aug; 12(4):877-902, viii. PubMed ID: 9759585 [TBL] [Abstract][Full Text] [Related]
18. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089 [TBL] [Abstract][Full Text] [Related]
19. [Future of malignant stage I melanoma. Immunology and immunotherapy]. Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476 [No Abstract] [Full Text] [Related]